Rituximab treatment in myasthaenia gravis

Report of two paediatric cases

Research output: Contribution to journalArticle

Abstract

Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.

Original languageEnglish
Pages (from-to)e223-e227
JournalSultan Qaboos University Medical Journal
Volume18
Issue number2
DOIs
Publication statusPublished - May 1 2018

Fingerprint

Cholinesterase Inhibitors
Oman
Pediatrics
Neuromuscular Junction
Drug-Related Side Effects and Adverse Reactions
Autoimmune Diseases
Skeletal Muscle
Quality of Life
Therapeutics
Rituximab
Sultan

Keywords

  • Case Report
  • Children
  • Cholinergic Receptors
  • Myasthenia Gravis
  • Oman
  • Rituximab

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Rituximab treatment in myasthaenia gravis : Report of two paediatric cases. / Koul, Roshan; AL-Fataisi, Amna; Abdelrahim, Rana; Mani, Renjith; Abdawani, Reem; Al-Aasmi, Abdullah.

In: Sultan Qaboos University Medical Journal, Vol. 18, No. 2, 01.05.2018, p. e223-e227.

Research output: Contribution to journalArticle

@article{aff82e2574a24953b3cacdae61328c55,
title = "Rituximab treatment in myasthaenia gravis: Report of two paediatric cases",
abstract = "Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.",
keywords = "Case Report, Children, Cholinergic Receptors, Myasthenia Gravis, Oman, Rituximab",
author = "Roshan Koul and Amna AL-Fataisi and Rana Abdelrahim and Renjith Mani and Reem Abdawani and Abdullah Al-Aasmi",
year = "2018",
month = "5",
day = "1",
doi = "10.18295/squmj.2018.18.02.018",
language = "English",
volume = "18",
pages = "e223--e227",
journal = "Sultan Qaboos University Medical Journal",
issn = "2075-051X",
publisher = "Sultan Qaboos University",
number = "2",

}

TY - JOUR

T1 - Rituximab treatment in myasthaenia gravis

T2 - Report of two paediatric cases

AU - Koul, Roshan

AU - AL-Fataisi, Amna

AU - Abdelrahim, Rana

AU - Mani, Renjith

AU - Abdawani, Reem

AU - Al-Aasmi, Abdullah

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.

AB - Myasthaenia gravis (MG) is an autoimmune disease involving the postsynaptic receptors in the neuromuscular junction. The condition is characterised by fatigable weakness of the skeletal muscles and is uncommon in children. Acetylcholinesterase inhibitors and immune-modifying medications are usually considered the mainstay of treatment. However, these medications have to be given on a lifelong basis so that patients remain in remission; furthermore, drug-related side-effects can have a major impact on quality of life. We report two paediatric cases who were treated for MG at the Sultan Qaboos University Hospital, Muscat, Oman, in 2007 and 2008, respectively. Rituximab was eventually administered to each patient after their condition failed to improve despite several years of standard treatment with acetylcholinesterase inhibitors and immune-modifying medications. Overall, rituximab resulted in complete remission in one case and significant clinical improvement in the other case.

KW - Case Report

KW - Children

KW - Cholinergic Receptors

KW - Myasthenia Gravis

KW - Oman

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=85053463460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053463460&partnerID=8YFLogxK

U2 - 10.18295/squmj.2018.18.02.018

DO - 10.18295/squmj.2018.18.02.018

M3 - Article

VL - 18

SP - e223-e227

JO - Sultan Qaboos University Medical Journal

JF - Sultan Qaboos University Medical Journal

SN - 2075-051X

IS - 2

ER -